Tag: exchange

BRIDGEWATER, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced first clinical proof-of-concept data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The results are being presented today in a late-breaking session at the European Hematology Association (EHA) 2026 Congress (Abstract #LB5006).

SHANGHAI, June 14, 2026 (GLOBE NEWSWIRE) -- French outdoor brand Salomon has officially unsealed the latest instalment of the ROAD TO THE FUTURE programme at the Anfu concept store in Shanghai, China. This event unveiled the full launch of the 2026 Road to the Future Design Competition. Guest designer Uma Wang joins eight emerging designers to debut exclusive collaborative footwear designs, coinciding with the public opening of the project’s in-store display and official launch of public voting phase. Salomon China brand ambassador Bai Jingting attended the opening event, uniting established designers, cross-industry professionals and industry medias to dissect the evolving trajectory of the emerging boundaries of outdoor and fashion industry. In the future, Salomon will continuously explore the boundaries of outdoor aesthetics through creativities.

Media Release

COPENHAGEN, Denmark; June 13, 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures --   

-- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS --

Kaunas, Lithuania, June 13, 2026 (GLOBE NEWSWIRE) --

An informational overview examining EpiCooler Portable AC Product Details, Publicly available product disclosures and what consumers often consider when researching portable cooling devices in 2026

DALLAS, June 12, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.^® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, announced today the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the purchase and sale of 3,883,496 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock and Series A-2 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock at a purchase price of $1.03 per share of common stock (or pre-funded warrant in lieu thereof) and associated preferred investment options.